TissueTech, Inc., a regenerative tissue-engineering company, received a $10m credit facility.
Square 1 Bank, the banking partner to entrepreneurs and the venture capital community, provided the financing.
The company intends to use the proceeds for the sales force expansion and pursuit of additional growth opportunities.
Incepted in 2001, TissueTech provides a portfolio of amniotic membrane and umbilical cord-based tissue and device products to the ophthalmology, optometry, orthopedic and wound care markets.
It operates through its commercial subsidiaries:
– Bio-Tissue® Inc., a provider of regenerative biologic therapies and ocular hygiene solutions for the treatment of ocular surface diseases and disorders, and
– Amniox® Medical Inc., a provider of regenerative tissue therapies to the musculoskeletal and wound care markets.